True hyperprolactinemia in men without visible pituitary adenoma.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
06 2021
Historique:
received: 12 10 2020
accepted: 09 01 2021
pubmed: 11 2 2021
medline: 9 7 2021
entrez: 10 2 2021
Statut: ppublish

Résumé

Men with mild to moderate hyperprolactinemia rarely present with normal pituitary on MRI with no visible adenoma, a condition entitled also "idiopathic hyperprolactinemia" or "non-tumoral hyperprolactinemia". We have characterized a cohort of hyperprolactinemic men with normal pituitary imaging. We have identified 13 men with true hyperprolactinemia and normal pituitary MRI. Baseline clinical and hormonal characteristics and response to medical treatment were retrospectively retrieved from medical records. Mean age at diagnosis was 51 ± 16 years (range, 20-77); mean serum prolactin level at presentation was 91 ng/ml (range, 28-264), eight men presented with low baseline testosterone. Initial complaints leading to diagnosis included sexual dysfunction in ten men and gynecomastia in five. All patients were treated with cabergoline, except for one who was given bromocriptine; none required pituitary surgery. All patients normalized prolactin and testosterone with subsequent clinical improvement reported by most men. Currently, after a mean follow-up of 72 months, ten patients continue treatment with caborgoline (median weekly dose, 0.25 mg), whereas three men discontinued treatment. Men with symptomatic hyperprolactinemia may rarely present with normal pituitary imaging. Medical treatment can lead to hormonal improvement with clinical benefit.

Identifiants

pubmed: 33566310
doi: 10.1007/s12020-021-02624-1
pii: 10.1007/s12020-021-02624-1
doi:

Substances chimiques

Prolactin 9002-62-4
Cabergoline LL60K9J05T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

809-813

Références

M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006)
doi: 10.1210/er.2005-9998
T. Mindermann, C.B. Wilson, Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. 41, 359–364 (1994)
doi: 10.1111/j.1365-2265.1994.tb02557.x
H. Duskin-Bitan, I. Shimon, Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020)
doi: 10.1007/s11102-019-01009-y
P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019)
doi: 10.1016/j.beem.2019.101290
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Eng. J. Med. 331, 904–909 (1994)
doi: 10.1056/NEJM199410063311403
A. Colao, A.D. Sarno, P. Cappabianca, F. Briganti, R. Pivonello, C.D. Somma, A. Faggiano, B. Biondi, G. Lombardi, Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325–331 (2003)
doi: 10.1530/eje.0.1480325
A.M. Lenz, A.W. Root, Empty sella syndrome. Ped. Endocrinol. Rev. 9, 710–715 (2012)
E. Horvath, K. Kovacs, B.W. Scheithauer, Pituitary hyperplasia. Pituitary 1, 169–179 (1999)
doi: 10.1023/A:1009952930425
J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano, The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412–418 (1989)
doi: 10.1210/jcem-68-2-412
A.K. Kalsi, A. Halder, M. Jain, P.K. Chaturvedi, J.B. Sharma, Prevalence and reproductive manifestations of macroprolactinemia. Endocrine 63, 332–340 (2019)
doi: 10.1007/s12020-018-1770-6
O.M. Hauache, A.J. Rocha, A.C. Maia Jr, R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. 57, 327–331 (2002)
doi: 10.1046/j.1365-2265.2002.01586.x
A. Glezer, M.D. Bronstein, Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J. Clin. Endocrinol. Metab. 97, 2211–2216 (2012)
doi: 10.1210/jc.2011-2976
A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, G. Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704–1711 (2004)
doi: 10.1210/jc.2003-030979
A.H. Zamanipoor Najafabadi, I.M. Zandbergen, F. de Vries, L.H.A. Broersen, M.E. van den Akker-van Marle, A.M. Pereira, W.C. Peul, O.M. Dekkers, W.R. van Furth, N.R. Biermasz, Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32–e41 (2020)
doi: 10.1210/clinem/dgz144
D. Maiter, E. Delgrange, Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014)
doi: 10.1530/EJE-14-0013

Auteurs

Ilan Shimon (I)

Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel. ilanshi@clalit.org.il.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. ilanshi@clalit.org.il.

Yaron Rudman (Y)

Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Yossi Manisterski (Y)

Maccabi Health Care Services, Tel Aviv, Israel.

Alex Gorshtein (A)

Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Hiba Masri (H)

Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Hadar Duskin-Bitan (H)

Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH